文献速递生殖医学

卵巢微环境:化疗相关卵巢损伤防护的挑战与机遇

Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage.
PubMed 文献 · Hum Reprod Update · 2024-01-01

本文综述了化疗期间卵巢微环境的变化,包括细胞外基质沉积、血管生成障碍、免疫微环境紊乱、氧化应激失衡、卵巢干细胞耗竭和细胞衰老,这些变化降低卵泡数量和质量。靶向卵巢微环境的干细胞治疗、自由基清除剂、衰老疗法、免疫调节剂和促血管生成因子等方法可能为化疗相关卵巢损伤提供潜在治疗途径,但卵巢微环境与化疗相关卵巢损伤的关系需进一步研究。

要点

  • 化疗可导致卵巢微环境改变,包括细胞外基质沉积和基质纤维化、血管生成障碍、免疫微环境紊乱、氧化应激失衡、卵巢干细胞耗竭和细胞衰老。
  • 靶向卵巢微环境的干细胞治疗、自由基清除剂、衰老疗法、免疫调节剂和促血管生成因子等方法已被用于防治化疗相关卵巢损伤。
  • 卵巢微环境在化疗相关卵巢损伤中起重要作用,但卵巢微环境、其调控网络与化疗相关卵巢损伤的关系需进一步研究。

核心结论

  • 卵巢功能由其「种子」(卵泡)和「土壤」(卵巢微环境)决定,靶向卵巢微环境可能为化疗相关卵巢损伤提供潜在治疗途径,但卵巢微环境、其调控网络与化疗相关卵巢损伤的关系需进一步研究。

研究设计与样本

  • 本综述通过检索PubMed截至2024年4月的文献,检索词包括卵巢微环境相关术语、卵巢功能相关术语和化疗药物相关术语。

主要发现

  • 化疗期间卵巢微环境发生显著变化,诱导细胞外基质沉积和基质纤维化、血管生成障碍、免疫微环境紊乱、氧化应激失衡、卵巢干细胞耗竭和细胞衰老,从而降低卵泡数量和质量。
  • 靶向卵巢微环境的干细胞治疗、自由基清除剂、衰老疗法、免疫调节剂和促血管生成因子等方法已被用于防治化疗相关卵巢损伤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 卵巢微环境、其调控网络与化疗相关卵巢损伤的关系需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy-associated ovarian damage (CAOD) is one of the most feared short- and long-term side effects of anticancer treatment in premenopausal women. Accumulating detailed data show that different chemotherapy regimens can lead to disturbance of ovarian hormone levels, reduced or lost fertility, and an increased risk of early menopause. Previous studies have often focused on the direct effects of chemotherapeutic drugs on ovarian follicles, such as direct DNA damage-mediated apoptotic death and primordial follicle burnout. Emerging evidence has revealed an imbalance in the ovarian microenvironment during chemotherapy. The ovarian microenvironment provides nutritional support and transportation of signals that stimulate the growth and development of follicles, ovulation, and corpus luteum formation. The close interaction between the ovarian microenvironment and follicles can determine ovarian function. Therefore, designing novel and precise strategies to manipulate the ovarian microenvironment may be a new strategy to protect ovarian function during chemotherapy. OBJECTIVE AND RATIONALE: This review details the changes that occur in the ovarian microenvironment during chemotherapy and emphasizes the importance of developing new therapeutics that protect ovarian function by targeting the ovarian microenvironment during chemotherapy. SEARCH METHODS: A comprehensive review of the literature was performed by searching PubMed up to April 2024. Search terms included 'ovarian microenvironment' (ovarian extracellular matrix, ovarian stromal cells, ovarian interstitial, ovarian blood vessels, ovarian lymphatic vessels, ovarian macrophages, ovarian lymphocytes, ovarian immune cytokines, ovarian oxidative stress, ovarian reactive oxygen species, ovarian senescence cells, ovarian senescence-associated secretory phenotypes, ovarian oogonial stem cells, ovarian stem cells), terms related to ovarian function (reproductive health, fertility, infertility, fecundity, ovarian reserve, ovarian function, menopause, decreased ovarian reserve, premature ovarian insufficiency/failure), and terms related to chemotherapy (cyclophosphamide, lfosfamide, chlormethine, chlorambucil, busulfan, melphalan, procarbazine, cisplatin, doxorubicin, carboplatin, taxane, paclitaxel, docetaxel, 5-fluorouraci, vincristine, methotrexate, dactinomycin, bleomycin, mercaptopurine). OUTCOMES: The ovarian microenvironment shows great changes during chemotherapy, inducing extracellular matrix deposition and stromal fibrosis, angiogenesis disorders, immune microenvironment disturbance, oxidative stress imbalances, ovarian stem cell exhaustion, and cell senescence, thereby lowering the quantity and quality of ovarian follicles. Several methods targeting the ovarian microenvironment have been adopted to prevent and treat CAOD, such as stem cell therapy and the use of free radical scavengers, senolytherapies, immunomodulators, and proangiogenic factors. WIDER IMPLICATIONS: Ovarian function is determined by its 'seeds' (follicles) and 'soil' (ovarian microenvironment). The ovarian microenvironment has been reported to play a vital role in CAOD and targeting the ovarian microenvironment may present potential therapeutic approaches for CAOD. However, the relation between the ovarian microenvironment, its regulatory networks, and CAOD needs to be further studied. A better understanding of these issues could be helpful in explaining the pathogenesis of CAOD and creating innovative strategies for counteracting the effects exerted on ovarian function. Our aim is that this narrative review of CAOD will stimulate more research in this important field. REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Guo Y, Xue L, Tang W, et al. Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage. Hum Reprod Update. 2024. PMID: 38942605. doi:10.1093/humupd/dmae020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。